Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: http://www.eurosurveillance.org / ViewArticle.aspx?ArticleId=21169


In this issue


Home Eurosurveillance Edition  2008: Volume 13/ Issue 15 Article 4
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 13, Issue 15, 10 April 2008
Rapid communications
Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales
  1. Sexually Transmitted Bacteria Reference Laboratory, Centre for Infections, Health Protection Agency, London, the United Kingdom

Citation style for this article: Chisholm SA, Ison C. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. Euro Surveill. 2008;13(15):pii=18832. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18832
Date of submission: 10 April 2008

The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales has monitored azithromycin resistance since 2001. In 2007, high-level azithromycin resistance (MICs >256 mg/L) was identified for the first time in six isolates, all of which were the same sequence type (ST 649).

High-level azithromycin resistance has also been reported in Scotland, but it is not known if this has wider geographical dissemination. It has been recommended that gonococcal resistance to azithromycin should be monitored in regions or countries where this drug is used to treat Chlamydia trachomatis infection. Furthermore, specific anti-gonococcal therapy should always be used to treat gonorrhoea. Azithromycin is not a recommended treatment for gonorrhoea in the United Kingdom [1]. Further information on this emerging resistance can be found at http://www.hpa.org.uk/hpr/archives/2008/hpr1408.pdf and http://www.dh.gov.uk/en/Publichealth/Patientsafety/Microbiologyandinfectioncontrol/DH_075723


References

  1. Clinical effectiveness group, British Association for Sexual Health and HIV.
    National Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults 2005. Available from: http://www.bashh.org/guidelines/2005/gc_final_0805.pdf


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.